Antibiotic resistance constitutes one of the most pressing public health concerns. 23
Antimicrobial peptides of multicellular organisms are considered part of a solution to 24 this problem, and AMPs produced by bacteria such as colistin are last resort drugs. 25
Importantly, antimicrobial peptides differ from many antibiotics in their 26 pharmacodynamic characteristics. Here we implement these differences within a 27 theoretical framework to predict the evolution of resistance against antimicrobial 28 peptides and compare it to antibiotic resistance. Our analysis of resistance evolution 29 finds that pharmacodynamic differences all combine to produce a much lower 30 probability that resistance will evolve against antimicrobial peptides. The finding can 31 be generalized to all drugs with pharmacodynamics similar to AMPs. 32
Pharmacodynamic concepts are familiar to most practitioners of medical 33 microbiology, and data can be easily obtained for any drug or drug combination. Our 34 theoretical and conceptual framework is therefore widely applicable and can help 35 avoid resistance evolution if implemented in antibiotic stewardship schemes or the 36 rational choice of new drug candidates. 37 including the MIC, the maximum effect and the steepness of the pharmacodynamics 116 curve are available ( Fig 1A, Fig 2C) . 117
118
Next we wanted to explore if the differences between AMPs and antibiotics in the 119 width of the MSW correlated with different probabilities of drug resistance evolution 120 within a host. A further difference between AMPs and antibiotics is that some 121 antibiotics increase mutagenesis but AMPs do not (17, 18) . We incorporated this 122 difference in addition to the difference in the steepness of the pharmacodynamics 123 relationship into a stochastic model describing bacterial replication and evolution 124 under selection pressure from AMPs. We consider two cases here: (a) do resistant 125 mutants emerge (answering this question requires a stochastic model) and (b) do 126 resistant mutants drive the susceptible strains to extinction? 127
128
We find that resistance emerges with a much higher probability for the parameter 129 settings of antibiotics (top row Fig 3B) than for AMPs in our simulations (bottom row 130 Fig 3B, Fig 3A) . All intermediate cases, where we simulated changes in one or two of 131 maximum effect, i.e. characteristics found in most common antibiotics, inherently 138 bears a high risk of causing the evolution of resistance. 139
We have shown before(10) that combinations of AMPs have higher κ and lower MICs 140 than individual AMPs. This also results in differences in resistance selection and the 141 extinction of susceptible strains, consistent with the results above. 142
143
Day et al (29) provided an approach to calculate a resistance hazard: a measure that 144 combines the time of resistance emergence and its selection within a host. We 145 calculated similar resistance hazard for AMPs in comparison to antibiotics. The 146 simulation results show (Fig 3C) that the hazard is much higher and the concentration 147 range much wider under antibiotic treatment than under AMP treatment. Also, when 148 resistance evolves, it emerges earlier in the antibiotic scenario than in the AMP 149 scenario at low concentrations (Fig 3D) . In certain concentrations (for example, 150 around MIC in our simulation), resistance emerges earlier in AMP than in antibiotics 151 (Fig 3D) . Time of emergence is mostly affected by κ and mutation rate: higher κ and 152 lower mutation rate, the latter more important when population sizes are small, confer 153 delayed resistance emergency (Fig S4) . 154 155 156
Discussion 157
Our predictions suggest that AMPs, or in fact any antimicrobial drug with similar 158 pharmacodynamics, are much less likely to select drug-resistant mutants than 159 antimicrobials with antibiotic-like characteristics. Our theory is blind to the molecular 160 mechanism of action but captures the dynamically relevant aspects of action. In the light of our results, increasing κ and/or the maximum effect are desirable for 168 any drug as well as advantageous to hosts managing their microbiota using AMPs. 169
Our model therefore provides useful information for the development of new 170 antimicrobial drugs: higher κ and maximum effect will impose much weaker selection 171 on the bacteria to evolve resistance in lower concentrations, and clear the bacterial 172 population more quickly in higher concentration which will, in turn, reduce the 173 probability of resistance emergence. Currently mostly AMPs display these properties, 174 but it is likely that new antibiotics that target the cell membrane or wall display 175 similar pharmacodynamics. argued that combination therapy reduces resistance evolution (but also see (32)), as it 207 is supposedly more difficult to evolve resistance against more than one mechanism at 208 a time. Our approach indicates that combination therapy might even prove effective if 209 there are mutations that confer complete cross-resistance to the drugs in the 210
combination. 211
It has been proposed that bacterial resistance evolution against AMPs is highly 213
unlikely (5, curves. This can also be achieved for drug combinations(10). A report by the 227 Leopoldina, the German National Academy of Sciences, recently recommended to 228 use new drugs only in combination to avoid fast resistance evolution(39). The 229 scientific support for this notion is limited and controversial (32, 40, 41) . In clinical 230 situations pharmacodynamic approaches can provide a first informed guess. Also, the 231 risk of resistance evolution based on the pharmacodynamics of drug candidates will 232 be a useful additional criterion to develop new drugs. We would also like to note that 233 the concept of the mutant selection window has been applied to understand antiviralresistance evolution(42), and hence our approach has the potential to inform antiviral 235 resistance research and ultimately treatment as well. 236
In order to generate predictions on resistance evolution based on pharmacodynamics, 237 one of our main goals of the project, we made a number of simplifying assumptions. 238
The pharmacodynamics are based on data of initial killing only. Moreover, we 239 assume homogeneous populations over time and space. Expanding the framework to 240 integrate tolerance and resistance is possible but would require pharmacodynamic 241 estimates and additional functions. Another possible extension of our work would be 242 to include pharmacodynamic estimates of resistant strains that change over time due 243 to compensatory mutations and to cross resistance or collateral sensitivity when 244 exposed to combinations of antimicrobials. Finally, we assumed the same 245 pharmacokinetics for all cases in our study. As AMPs are currently rarely used 246 (Colistin being the notable exception), future empirical work will inform realistic 247 parameter estimates for pharmacokinetics. In all cases however, the basis of any 248 analysis concerning resistance evolution is the influence of individual 249 pharmacodynamic parameters, for which we provide a framework. 
Materials and Methods 255
For the parameterization of the predictive models, we used two main sources. The 256 pharmacodynamic parameters are taken from one of our own studies that determines 257 pharmacodynamics for AMPs and antibiotics under standardized conditions(10). In 258 short, time kill experiments with different AMP concentrations were conducted andthe slopes of the linear regressions were used to calculate the parameters of the 260 pharmacodynamic function. Here, we only took into account the intial kill rates and 261 assumed a homogeneous population structure. The estimates of mutation rates again 262 are from our own comparative study on mutagenesis under AMP and AB 263 treatment(17) . 264
265

Calculation of the size of the mutant selection window 266
The size of the mutant selection window (MSW) depends on the lower and upper 267 bound of the MSW and is calculated as 268
The lower bound of the MSW is the concentration for which the net growth rate of the 270 resistant strain is equal to the net growth rate sensitive strain and is called the minimal 271 selective concentration (MSC). The upper bound of the MSW is the MIC of the 272 resistant strain (MIC R ) (Fig 1 A) . 273
To analytically describe the MSW, we use the pharmacodynamic (PD) function ( ), 274 which mathematical describes the net growth rate with a Hill function: 275 (43)). The Hill coefficient κ describes the steepness of 282 the curve; functions with higher κ describe steeper curves (Fig 2A) . For illustration ofthe pharamcodynamic parameters see Fig S3) . Cost of resistance is included as a 284 reduction of the maximum growth rate of the resistant strain in absence of 285 antimicrobials with c = 1-ψ max,R /ψ max,S (Fig 1A, 2A) . The pharamcodynamic 286 function can be described for both a drug susceptible strain S and a drug-resistant 287 strain R, with ψ S (a) and ψ R (a) , respectively. The MSC is calculated as ψ S (a) = ψ R (a). 288
We assume that the net growth rate of the resistant strain below the MSC is, for any 289
given concentration a, with 0 < a < MSC, approximately at the same level as without 290 antimicrobials and therefore we set ψ R (a) ≈ ψ R,approx (illustrated in Fig 2A) . We therefore assumed similar relationships for both antibiotics and AMPs. 304
We calculated cost of resistance c as c = 1 -fitness, using n= 128 observations 305 compiled in the mentioned dataset. Fitting a log10 transformed linear regressiondetermine the 95% confidence interval of log-linear regression of the data as 309 interval, where 95 % of the regression fall into (see fig. 2B ) and (ii) to include the 310 variance of the data when determining the size of the mutant selection window 311 (MSW)(see fig. 2C ). For the latter, the given dataset was fitted to the mentioned 312 log-linear regression 200 times, resulting in 200 parameter sets for the 313 regression. Each parameter set was then used to calculate the size of the MSW 314 depending on the cost of resistance. The 95% confidence interval was then 315 calculated as the interval, in which 95% of the calculated size of the MSW are in 316 for a given cost. 317
318
Model of evolution and prediction of resistance 319
To study resistance evolution we used a mathematical model that incorporates 320 pharmacodynamics (PD) and pharmacokinetics (PK) and captures population 321 dynamics of bacterial populations under treatment with antimicrobial drugs(20). We 322 ran stochastic simulations to calculate the probability of resistance emergence, the 323 probability of the resistant strain, the time to resistance emergence and the risk of 324 resistance (the resistance hazard (29)). 325
326
To simulate treatment, we consider a patient harboring 10 6 susceptible bacteria. 327
Bacterial mutation rates are assumed to depend on the antimicrobial used for 328 treatment (antibiotics or AMPs). When a resistant strain arises it is assumed to have 329 an MIC ten-fold that of susceptible wild-type strain. For simplicity, we only consider 330 one type of mutant. Antimicrobials are administered every day (see Supplement for 331 pharmacokinetics), and treatment lasts one week.
The population dynamics of the susceptible and resistant strains is captured in the 333
following system of differential equations: 334
338
Where S represents the wild-type strain and R represents the resistant strain. The 339 maximum net growth rate ψ max is the difference between the replication rate r and the 340 intrinsic death rate d n : ψ max = r-d n . µ is the mutation rate. 341
342
To include the change of antimicrobial concentrations over time (pharmacokinetics) 343 into our mode, we define the death rate to be dependent on the time-dependent 
347
We assume a time-dependent pharmacokinetic function a(t) of the following form 348 (see also Fig S2) : 349 ( ) 
352
Here, k a is the absorption rate, and k e is the decay rate. D is the dose given each time, 353 n is the number of doses, τ is the dosing frequency. We define the treatment dose as 354 the average concentration in the course of treatment: 355
algorithm (45), which allowed us to monitor how frequently mutants arise. Parameters 359 were selected based on empirical data as stated above. The net growth rate of wild-360 type in the absence of antimicrobials was set as 1. Mutants suffer fixed or resistant-361 level related costs (see Fig 2) . κ of AMPs and antibiotics were set as 5 and 1.5, 362 respectively (10). ψ min for AMPs is fixed as -50 hour -1 ; and for antibiotics is fixed as -363 5 hour -1 . Mutation rates in AMPs are assumed to be three times lower than in 364 antibiotics, in accordance with our empirical estimates (17). All the parameters and 365 their values are listed in Table S1 . All the pharmacokinetic parameters are the same in 366 different simulations (see Fig S2) . For each set of parameters, cohorts of five hundred 367 infected individuals were simulated. Successful treatment is defined as complete 368 clearance of both sensitive and resistant strains at the end of the one-week treatment. 369
For each cohort, we calculate the probability of treatment success as the proportion of 370 individuals in whom treatment was successful. In each individual, we score the time 371 of emergence of resistance strains, and estimate the resistance hazard based on the 372 average probability of treatment success and the population size of bacteria over time. 373
The hazard function can be written as, 374
where K is the capacity, S denotes population size of sensitive strain and p S→R is 376 probability of a treatment developing resistance, which is calculated from the results 377 of simulations, ψ R is the growth rate of resistant strain. Our hazard function calculates 378 the average proportion of resistant population under certain treatment dose and 379 duration. range in which resistant mutants are selected (13) . Following (14), we determine the 529 MSW using net growth curves of a susceptible strain S and a resistant strain R. 530
Mathematically, net growth is described with the pharmacodynamic function ( ) 531
( (20), see Materials and Methods and Fig S3 for details) . In short, the function 532 consists of the four pharamcodynamic parameters: net growth in absence of 533 antibicrobials !"# , net growth in the presence of a dose of antimicrobials, which 534 effects the growth maximal, !"# , the MIC and the parameter κ, which describes the 535 steepness of the pharamcodynamic curve. Here, the two pharmacodynamics functions 536 ! ( ) (continuous pink line) and ! ( ) (dotted black line) describe the net growth 537 of the S and R, respectively, in relation to the drug concentration a. Cost of resistance 538 is included as a reduction of the maximum growth rate of the resistant strain 539 The lower boundary of the MSW (MSC) depends primarily on the pharmacodynamic 556 parameters of the sensitive strain, assuming that the net growth rate of the resistant 557 strain below the MSC is approximately at the same level as without antimicrobials: 558 The upper boundary of the MSW is per definition the ! , which is linked to its 566 fitness cost, i.e. the upper boundary ! increases with costs (data from (44)). 567
Here, the log-linear regression and the 95% confidence interval are plotted. (29) we 592 calculate the resistance hazard as the time-averaged proportion of mutants in a patient 593 under a particular treatment dose. We find that AMPs are much less likely to select 594 for resistance across concentrations than antibiotics (inset graph: a log-scale view). 
